Radiologists are using DBT for breast cancer screening, but it still is a limited resource.
Digital breast tomosynthesis (DBT) is becoming more common but remains a limited resource, according to a study published in the Journal of the American College of Radiology.
Researchers from the University of Colorado Denver in Aurora assessed the utilization of DBT and the criteria for offering DBT to patients. The researchers distributed an online survey for physician members of the Society of Breast Imaging to assess their use of DBT. The questions covered availability of DBT at the participant's practice, whether DBT was used for clinical care or research, clinical decision rules guiding patient selection for DBT, costs associated with DBT, plans to obtain DBT, and breast imaging practice characteristics.
The results showed a response rate of 37% (670 members); 30% (200 respondents) reported using DBT, with 89% using DBT clinically. Participants were more likely to report DBT use if they worked at an academic practice, a practice with more than three breast imagers, or a practice with seven or more mammography units. Criteria used to select patients to undergo DBT varied:
• 107 physicians (68.2%) used exam type (screening versus diagnostic)
• 25 (15.9%) used mammographic density
• 25 (15.9%) used breast cancer risk
Fees for DBT ranged from $25 to $250. In addition, 62.3% of nonusers planned to obtain DBT.
The researchers concluded that DBT is becoming more common but remains a limited resource. Clinical guidelines would assist practices in deciding whether to adopt DBT and in standardizing which patients should receive DBT.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.